A New Calcipotriol/Betamethasone Formulation with Rapid Onset of Action was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis Vulgaris

Douglas, W. S.; Poulin, Y.; Decroix, J.; Ortonne, J. P.; Mrowietz, U.; Gulliver, W.; Krogstad, A. L.; Larsen, F. G.; Iglesias, L.; Buckley, C.; Bibby, A. J.
March 2002
Acta Dermato-Venereologica;Mar2002, Vol. 82 Issue 2, p131
Academic Journal
In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone[sup ®]) and calcipotriol ointment (Daivonex[sup ®]) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% CI) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.(-22.8 to -15.2, p < 0.001). The differences in PASI were also statistically significant after 1 week. In the double-blind phase, 8.1% of patients (combination) reported lesional/perilesional adverse reactions compared to 4.7% (betamethasone) and 12.0% (calcipotriol). In the combination group, mean PASI at the end of the double-blind phase was 2.5, and at end of the unblinded phase 3.6, compared with 3.9 and 4.1 (betamethasone) and 4.4 and 3.7 (calcipotriol). Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated. It is safe to transfer patients from combination to calcipotriol, with maintenance of clinical effect.


Related Articles

  • Psoriasis: Flaky is only an adjective for piecrusts. Schaefer, Ingrid K. // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS3 

    Editorial. Contemplates on the advances in psoriasis care. Effectiveness of over-the-counter remedies on psoriasis; Challenge for manufacturers to come up with a more effective treatment for proriasis.

  • FDA okays psoriasis indication for a cyclosporine.  // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS25 

    Presents highlights of the Neoral labeling related top psoriasis. Considerations before initiating treatment with the drug; Initial recommended dose for patients with psoriasis; Cautions against the use of Neoral for longer than a year.

  • Patient Education Critical Factor in Successful Tazarotene Use. Moore, Ian J.S. // Dermatology Times;Feb98, Vol. 19 Issue 2, p45 

    States that tazarotene can be used successfully as a first-line treatment in psoriatic patients when they are properly instructed about its use. Factors to consider in prescribing the drug for psoriasis treatment; Common side effects of psoriatic treatment; How to manage the side effects of...

  • Psoriasis solution. Segell, Michael // Cosmopolitan;Sep95, Vol. 219 Issue 3, p94 

    Suggests a treatment for the skin disease called psoriasis. Estimated number of Americans afflicted with psoriasis; Cause of disease; Experimental therapy that may lead to discovery of drug for disease.

  • Oral Tazarotene. Guttman, Cheryl // Dermatology Times;May2003, Vol. 24 Issue 5, p24 

    Focuses on the use of oral tazarotene in treating psoriasis. Side effects of the drug; Mechanism of action.

  • No Differences. Guttman, Cheryl // Dermatology Times;May2003, Vol. 24 Issue 5, p26 

    Focuses on the use of Alefacept (Amevive) in treating chronic plaque psoriasis. Candidates for systemic therapy or phototherapy; Side effects of the drug; Mechanism of action.

  • PSORIASIS BRIEFS.  // Dermatology Times;May2003, Vol. 24 Issue 5, p27 

    Presents news items related to psoriasis as of May 2003. Effectiveness of Alefacept in treating psoriasis; Promotion of psoriasis drug Donovex.

  • Soriatane Label Revised. Guttman, Cheryl // Dermatology Times;May2003, Vol. 24 Issue 5, p30 

    Focuses on the use of acitretin in treating psoriasis. Effectiveness of the drug; Contraindications; Usage.

  • Quality of life tantamount in Psoriasis therapy. Moyer, Paula // Dermatology Times;Mar1999, Vol. 20 Issue 3, p15 

    States that the degree of treatment of the skin disease psoriasis should depend on how the condition affects the patient's ability to function at home and at home. Variation in the spectrum of severity; Need for the examination of a patient's total body surface; Need to educate patients on the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics